Onbrez Breezhaler

Showing 4 posts of 4 posts found.

FDA delays decision on Novartis’ COPD drug

March 23, 2011
Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol

The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …

Novartis’ COPD drug recommended for FDA approval

March 10, 2011
Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol

Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …

GSK’s Seretide/Advair

New COPD and asthma treatments jostle for market space

October 6, 2010
Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma

Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …

Novartis hails longer-lasting COPD drug

September 20, 2010
Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler

A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …

The Gateway to Local Adoption Series

Latest content